Compare VRTX & METAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Meta Platforms Inc. Depositary Shares representing a 1/20th Interest in a Share of Series A Mandatory Convertible Preferred Stock
Current Price
| Metric | VRTX | METAM |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Programming Data Processing |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 125.8B |
| IPO Year | 2007 | 2012 |
| Metric | VRTX | METAM |
|---|---|---|
| Price | $517.10 | $46.42 |
| Analyst Decision | Buy | |
| Analyst Count | 32 | 0 |
| Target Price | ★ $595.36 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 2.8M |
| Earning Date | 11-02-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | 10.90 | ★ 20.44 |
| Revenue | $2,488,652,000.00 | ★ $40,653,000,000.00 |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $10.53 | N/A |
| P/E Ratio | $47.77 | ★ $2.38 |
| Revenue Growth | 46.20 | ★ 47.09 |
| 52 Week Low | $412.27 | $48.58 |
| 52 Week High | $568.67 | $52.09 |
| Indicator | VRTX | METAM |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 19.58 |
| Support Level | $493.75 | N/A |
| Resistance Level | $536.58 | $52.09 |
| Average True Range (ATR) | 15.90 | 1.33 |
| MACD | -3.73 | -0.41 |
| Stochastic Oscillator | 4.74 | 7.19 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).